Loading cancer entity…
Loading cancer entity…
Clinical trials
217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07194044 | Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes(METTSEO) | recruiting | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07297979 | Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) | recruiting | Phase 1 | 50 | AmgenINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06926283 | A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors | recruiting | Phase 1 | 110 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07830667 | A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat | not yet recruiting | Phase 1 / Phase 2 | 79 | Children's Oncology GroupNETWORK | 0 | Sep 22, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT07695311 | EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT | not yet recruiting | Phase 1 | 24 | Rabi HannaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | recruiting | Phase 1 | 411 | Inhibrx Biosciences, IncINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06156410 | Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | recruiting | Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | recruiting | Phase 1 / Phase 2 | 265 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06541262 | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 104 | Milton S. Hershey Medical CenterOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT05918640 | Lurbinectedin in FET-Fused Tumors(LiFFT) | recruiting | Phase 1 / Phase 2 | 63 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03356782 | Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04433221 | Combination Immunotherapy Targeting Sarcomas | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors(Regbone) | completed | Phase 1 / Phase 2 | 30 | Institute of Mother and Child, Warsaw, PolandOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07172958 | Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)(SABRE) | recruiting | Phase 1 | 18 | Children's National Research InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04337177 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | active not recruiting | Phase 1 | 20 | Valent Technologies, LLCINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | active not recruiting | Phase 1 | 94 | Baylor College of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07197554 | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 171 | SEED Therapeutics, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT06094101 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)(PerVision) | recruiting | Phase 1 / Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04308330 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies(NYMC195) | recruiting | Phase 1 | 30 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06566092 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | active not recruiting | Phase 1 | 40 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04890093 | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | suspended | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas | recruiting | Phase 1 / Phase 2 | 63 | David S Shulman, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07222735 | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas | recruiting | Phase 1 | 42 | St. Jude Children's Research HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05734066 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 60 | Jazz PharmaceuticalsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | recruiting | Phase 1 | 25 | Baylor College of MedicineOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05830084 | Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma(REGO-INTER-EWI) | active not recruiting | Phase 1 | 23 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Jan 6, 2026 | clinicaltrials |
| NCT01858168 | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma | completed | Phase 1 | 49 | Massachusetts General HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04067115 | SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients(U01CA236220) | completed | Phase 1 / Phase 2 | 37 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03514407 | A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 4 | Oct 21, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | terminated | Phase 1 | 19 | 3B Pharmaceuticals GmbHINDUSTRY | 2 | Aug 24, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02657005 | TK216 in Patients With Relapsed or Refractory Ewing Sarcoma | terminated | Phase 1 / Phase 2 | 85 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02076906 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | completed | Phase 1 | 7 | AeRang KimOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | terminated | Phase 1 | 74 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 13 | HutchmedINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT06340204 | Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma | recruiting | Phase 1 | 44 | Peking University People's HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials